Stock Price Prediction

CSCI stock is currently trading at $2.83, with a neutral RSI of 50.72, indicating no strong overbought or oversold conditions. The company has streamlined operations, focusing on Avenanthramides Tablets, but recent cost-cutting measures and management changes have not significantly boosted investor confidence, as reflected in a 1.97% premarket drop in December. Near-term resistance is at $2.93, with support at $2.66, suggesting limited upside unless positive catalysts emerge.

CSCI stock currently trades at $2.83, reflecting a bearish outlook due to its recent operational restructuring and pipeline setbacks. The discontinuation of macimorelin development after a failed Phase 3 trial and cost-cutting measures, including management terminations, signal challenges in achieving growth. Additionally, the stock's 2.41% decline in regular trading on February 28 indicates weak investor confidence.